This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Michael A. McEwan: Innovator in Hedgehog Signaling Pathway Modulation
Introduction
Michael A. McEwan is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biomedical research, particularly in the modulation of the Hedgehog signaling pathway. His work is crucial for the diagnosis and treatment of various pathologies, including cancer.
Latest Patents
Michael A. McEwan holds a patent for "Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway." This patent relates to compounds that are instrumental in diagnosing and treating conditions associated with the Hedgehog pathway, such as tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders. He has 1 patent to his name.
Career Highlights
Michael is currently employed at Novartis AG, a leading global healthcare company. His role involves extensive research and development in the field of pharmaceuticals, focusing on innovative solutions for complex health issues.
Collaborations
Throughout his career, Michael has collaborated with esteemed colleagues, including Miao Dai and Feng He. These partnerships have enhanced the scope and impact of his research.
Conclusion
Michael A. McEwan's contributions to the field of biomedical research, particularly through his patent on Hedgehog pathway modulators, highlight his role as an innovator in the industry. His work continues to pave the way for advancements in cancer treatment and diagnosis.